Inspra (Eplerenone)

Eplerenone selectively blocks mineralocorticoid receptors in the kidney’s distal tubules, preventing aldosterone from promoting sodium reabsorption. This results in increased excretion of sodium and water, retention of potassium, and a reduction in blood volume, which together lower blood pressure and provide protective effects in heart failure.

The appropriate dose of Inspra is determined by the prescribing healthcare professional based on the individual’s medical condition, renal function, and electrolyte status. Dosage adjustments may be needed for patients with kidney impairment or those taking other medications that affect potassium levels.

Safety of Inspra in pregnancy and lactation has not been fully established. It should only be used if the potential benefits justify the potential risks to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Inspra product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Inspra (eplerenone) is more selective for mineralocorticoid receptors than some older agents, resulting in fewer endocrine side effects such as gynecomastia. However, both classes share similar risks of hyperkalaemia and require monitoring of renal function and electrolytes.

Inspra tablets should be stored at room temperature, below 25 °C, in their original packaging. Keep them away from moisture, heat, and direct sunlight to maintain stability and potency.

Inspra is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most critical risks include severe hyperkalaemia, which can cause cardiac arrhythmias, and acute kidney injury. Patients should have regular laboratory monitoring of serum potassium and renal function, especially when starting therapy or adjusting doses.

Inspra is contraindicated in individuals with known hypersensitivity to eplerenone, severe renal impairment, or baseline hyperkalaemia. It should also be avoided in patients taking other potassium‑sparing agents unless closely supervised by a healthcare professional.